Viridian Therapeutics, Inc.\DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.\DE operating margin
Operating margin is operating income as a percentage of revenue.
Viridian Therapeutics, Inc.\DE's operating margin for the twelve months ending Jun 30, 2026 was -569.7%. For fiscal 2025 it was -512.9%, against -99018.2% the year before. The highest annual figure on record is -3.6% in fiscal 2013.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -512.9% | +98505.3 |
| FY2024 | Dec 31, 2024 | -99018.2% | −17983.2 |
| FY2023 | Dec 31, 2023 | -81035.0% | −73455.8 |
| FY2022 | Dec 31, 2022 | -7579.2% | −4888.4 |
| FY2021 | Dec 31, 2021 | -2690.8% | +7821.6 |
| FY2020 | Dec 31, 2020 | -10512.4% | −9571.4 |
| FY2019 | Dec 31, 2019 | -941.0% | −546.5 |
| FY2018 | Dec 31, 2018 | -394.5% | +268.3 |
| FY2017 | Dec 31, 2017 | -662.8% | −174.2 |
| FY2016 | Dec 31, 2016 | -488.6% | −47.8 |
| FY2015 | Dec 31, 2015 | -440.8% | −334.9 |
| FY2014 | Dec 31, 2014 | -105.9% | −102.3 |
| FY2013 | Dec 31, 2013 | -3.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -44460.6% | +97895.4 |
| Q1 FY2026 | Mar 31, 2026 | -82389.4% | +47980.1 |
| Q4 FY2025 | Dec 31, 2025 | -92991.7% | +28497.2 |
| Q3 FY2025 | Sep 30, 2025 | -56.7% | +97013.1 |
| Q2 FY2025 | Jun 30, 2025 | -142356.0% | −42096.3 |
| Q1 FY2025 | Mar 31, 2025 | -130369.4% | −52734.7 |
| Q4 FY2024 | Dec 31, 2024 | -121488.9% | −22213.9 |
| Q3 FY2024 | Sep 30, 2024 | -97069.8% | −25925.3 |
| Q2 FY2024 | Jun 30, 2024 | -100259.7% | −17933.3 |
| Q1 FY2024 | Mar 31, 2024 | -77634.7% | −3682.7 |
| Q4 FY2023 | Dec 31, 2023 | -99275.0% | −52545.5 |
| Q3 FY2023 | Sep 30, 2023 | -71144.4% | −68652.0 |
| Q2 FY2023 | Jun 30, 2023 | -82326.4% | −70778.0 |
| Q1 FY2023 | Mar 31, 2023 | -73952.0% | −61966.4 |
| Q4 FY2022 | Dec 31, 2022 | -46729.5% | −33140.3 |
| Q3 FY2022 | Sep 30, 2022 | -2492.5% | +4302.7 |
| Q2 FY2022 | Jun 30, 2022 | -11548.4% | −9897.2 |
| Q1 FY2022 | Mar 31, 2022 | -11985.6% | −10709.6 |
| Q4 FY2021 | Dec 31, 2021 | -13589.3% | +154184.8 |
| Q3 FY2021 | Sep 30, 2021 | -6795.2% | −3001.1 |
| Q2 FY2021 | Jun 30, 2021 | -1651.2% | −685.3 |
| Q1 FY2021 | Mar 31, 2021 | -1276.0% | −131.6 |
| Q4 FY2020 | Dec 31, 2020 | -167774.1% | −166158.2 |
| Q2 FY2020 | Jun 30, 2020 | -3794.0% | −3438.4 |
| Q1 FY2020 | Mar 31, 2020 | -965.9% | +2188.9 |
| Q4 FY2019 | Dec 31, 2019 | -1144.4% | +1051.6 |
| Q3 FY2019 | Sep 30, 2019 | -1615.8% | −646.4 |
| Q2 FY2019 | Jun 30, 2019 | -355.7% | +50.4 |
| Q1 FY2019 | Mar 31, 2019 | -3154.8% | −3058.3 |
| Q4 FY2018 | Dec 31, 2018 | -2196.0% | −1663.0 |
| Q3 FY2018 | Sep 30, 2018 | -969.4% | −608.3 |
| Q2 FY2018 | Jun 30, 2018 | -406.1% | +617.6 |
| Q1 FY2018 | Mar 31, 2018 | -96.6% | +1405.4 |
| Q4 FY2017 | Dec 31, 2017 | -533.1% | +628.8 |
| Q3 FY2017 | Sep 30, 2017 | -361.1% | +75.0 |
| Q2 FY2017 | Jun 30, 2017 | -1023.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -1501.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -1161.9% | – |
| Q3 FY2016 | Sep 30, 2016 | -436.1% | – |
See a number that looks wrong?